Ionis Pharmaceuticals, Inc. (IONS) Stock

Ionis Pharmaceuticals, Inc. (IONS) is a Healthcare stock trading at $74.13 (as of 2026-06-18), with a market capitalization of $12.64B and a trailing P/E of -36.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Ionis Pharmaceuticals, Inc. develops and commercializes RNA-targeted therapeutics for a range of diseases. Its marketed treatments include SPINRAZA, TEGSEDI, and WAYLIVRA, and it also has medicines in phase 3 for conditions such as transthyretin amyloidosis and other metabolic and neurological disorders, with products used in the United States.

Valuation — source: SEC EDGAR (first-party)
Price$74.13
Market Cap$12.64B
P/E Ratio-36.5
EV / EBITDA-40.1
Price / Book24.64
Price / Sales11.44
DCF Value (model)$-41.38
DCF Upside vs Price-155.8%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$943.71M
Net Margin-40.4%
Return on Equity-66.5%
Debt / Equity3.58
Current Ratio4.10
Revenue Growth (YoY)87.0%
EPS Growth (YoY)-39.8%
FCF Growth (YoY)398.7%
Financial Health — source: SEC EDGAR
Altman Z-Score2.04 (grey)
Piotroski F-Score3/9 (weak)
Valuation vs Sector & Industry
Stock P/E-36.5
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-273.9%
vs Industry-311.2%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFMR LLC ($1.84B)
Institutional Holders Tracked10
Congressional Trades (recent)1
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOBrett Monia
Employees1,069
CountryUS
IPO Date1991-05-17

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • BridgeBio Pharma, Inc. (BBIO)
  • Summit Therapeutics Inc. (SMMT)
  • Madrigal Pharmaceuticals, Inc. (MDGL)
  • Moderna, Inc. (MRNA)
  • Exelixis, Inc. (EXEL)
  • BioMarin Pharmaceutical Inc. (BMRN)
  • Radiopharm Theranostics Limited (RADX)
  • Elanco Animal Health Incorporated (ELAN)
IONS earnings history · IONS institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.